ClinicalTrials.gg
CompletedNCT03112174SYMPATICOUpdated Jul 22, 2025Results posted

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

A Phase 3 interventional study of Ibrutinib and Venetoclax in Mantle-Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 120 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing venetoclax in Lymphoma, Mantle-Cell — 5 open to participants now, 13 under way, none of them phase 3. venetoclax · Lymphoma, Mantle-Cell.

Enrollment
Largest of 23
366 · median 37
Started
2017
with 1 other
Phase 3
Only one
of the 23
Registered
4th of 23
by date

Among the 23 studies testing venetoclax in Lymphoma, Mantle-Cell, this one has the largest enrollment, is one of 2 that started in 2017, is the only one in phase 3, and was the 4th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 23 studies testing venetoclax in Lymphoma, Mantle-Cell are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing venetoclax in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

03

Conditions studied

  • Mantle-Cell Lymphoma

Keywords

  • PCYC
  • MCL
  • Non-Hodgkin's Lymphoma
  • NHL
  • ibrutinib
  • venetoclax
  • Pharmacyclics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Arm

Inclusion Criteria:

  • confirmed MCL (in tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR).
  • At least 1 measurable site of disease on cross-sectional imaging (CT).
  • At least 1, but no more than 5, prior treatment regimens for MCL.
  • Failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.
  • Subjects must have adequate fresh or paraffin embedded tissue.
  • Adequate hematologic, hepatic and renal function.
  • (ECOG) performance status (PS) of \<= 2.

Exclusion Criteria:

  • History or current evidence of central nervous system lymphoma.
  • Concurrent enrollment in another therapeutic study or prior therapy with ibrutinib or other BTK inhibitors.
  • Prior treatment with venetoclax or other BCL2 inhibitors.
  • Anticancer therapy including chemotherapy, radiotherapy, small molecule and investigational agents \<= 21 days prior to receiving the first dose of study drug.
  • Treatment with any of the following within 7 days prior to the first dose of study drug: moderate to strong cytochrome P450 3A () inhibitors or strong CYP3A inducers.

Treatment Naïve Arm

Inclusion Criteria:

  • Pathologically confirmed treatment-naive MCL (tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14), as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR).
  • Men and women ≥18 years of age with a TP53 mutation.
  • At least 1 measurable site of disease by CT.
  • Must have adequate fresh or paraffin-embedded tissue.
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0 to \<= 2.
  • Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

  • Blastoid variant of MCL
  • History or current evidence of CNS lymphoma.
  • Concurrent enrollment in another therapeutic investigational study or prior therapy including ibrutinib or other BTK inhibitors.
  • Prior treatment with venetoclax or other BCL2 inhibitors.
  • Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug.
  • infection requiring IV systemic treatment that was completed \<=14 days before the first dose of study drug.
  • Any uncontrolled active systemic infection.
  • Known bleeding disorders (eg, von Willebrand's disease or hemophilia).
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • History of or active or .
  • Major surgery within 4 weeks of the first dose of study drug.
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the participant's safety or put the study outcomes at undue risk.
  • Currently active, clinically significant cardiovascular disease; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  • Unable to swallow capsules or tablets, or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  • Treatment with any of the following within 7 days prior to the first dose of study drug: Moderate or strong cytochrome P450 3A (CYP3A) inhibitors or moderate or strong CYP3A inducers.
  • Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects with known risk factors (as defined by high tumor burden and/or diminished renal function, as detailed in "Study Design" section above) for TLS.
  • Chronic liver disease with hepatic impairment class B or C.
  • Unwilling or unable to participate in all required study evaluations and procedures.
  • Known to the active ingredient or other components of one or more study drugs.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Safety Run-in

    Participants with a low or high risk of TLS enroll into the open-label Safety Run-in Period to receive concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramp up to a target dose of 400 mg once daily over a 5-week period.

    Drug: Ibrutinib · Drug: Venetoclax

  • Experimental
    Randomization Phase: Ibrutinb + Venetoclax

    Participants randomized to ibrutinib and venetoclax for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax is discontinued after 104 weeks of treatment, regardless of response assessment.

    Drug: Ibrutinib · Drug: Venetoclax

  • Placebo comparator
    Randomization Phase: Ibrutinib + Placebo

    Participants randomized to ibrutinib and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo is discontinued after 104 weeks of treatment, regardless of response assessment.

    Drug: Ibrutinib · Drug: Placebo Oral tablet to match Venetoclax

  • Experimental
    Treatment-naive Open-label Arm

    Participants are treated with ibrutinib 560 mg and venetoclax 400 mg, administered using the 5-week ramp-up schedule.

    Drug: Ibrutinib · Drug: Venetoclax

Interventions

  • Administered orally once daily

  • Administered orally once daily

  • DrugPlacebo Oral tablet to match Venetoclax

    Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)

    TLS events are defined as follows: * Clinical TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) with the following exceptions: * For the purpose of TLS assessment during the Safety Run-in Period, only those increases in serum creatinine \> 1.0 mg/dL from pre-treatment baseline will be considered clinical TLS. * In participants with renal dysfunction at baseline (CrCl \< 60 mL/min), clinical TLS is defined as the presence of laboratory TLS plus either seizures, cardiac dysrhythmia, or death. * Laboratory TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) for laboratory TLS, that does not resolve within 72 hours despite protocol required management.

    Time frame: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months

  2. Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)

    DLT: any Grade (Gr) 3 or higher non-TLS adverse event (AE) at least possibly related to study drug occurring during the DLT assessment period with the following clarifications: Non-Hematologic DLTs: Gr ≥3 nausea, vomiting or diarrhea uncontrolled despite maximum medical supportive care and persisting \>5 days; Gr 3 fatigue persisting \>7 days; Gr 3 infection is not a DLT, however an infection with lifethreatening consequences or requiring urgent intervention (Gr 4) was considered a DLT; Treatment delay of any study drug \>7 days for toxicity. Hematologic DLTs: Gr 3 neutropenia is not a DLT, however, Gr 4 neutropenia (ANC \<500/mm\^3) lasting for \> 7 days is a DLT; Gr 3 or 4 neutropenia complicated by fever ≥38.5°C or infection; Gr 4 thrombocytopenia (\<25,000/mm\^3) that persists for \> 7 days; Gr 3 or 4 thrombocytopenia associated with Gr 2 or greater bleeding; Gr 3 anemia is not a DLT, however, Gr 4 anemia is a DLT; Treatment delay of any study drug \>7 days for hematologic toxicity.

    Time frame: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months

  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)

    AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

    Time frame: From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months

  4. Progression-free Survival (PFS) (Randomization Phase)

    PFS is defined as the time from the date of randomization to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

    Time frame: For an overall median time on study of 61.34 months

  5. Complete Response (CR) Rate (Treatment-Naive Arm)

    CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: For an overall median time on study of 40.51 months

Secondary outcomes

  1. Overall Survival (OS) (Safety Run-in)

    OS is defined as the time from the date of the first dose of study treatment to death from any cause.

    Time frame: For an overall median time on study of 74.78 months

  2. Progression-free Survival (PFS) (Safety Run-in)

    PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

    Time frame: For an overall median time on study of 74.78 months

  3. Duration of Response (DOR) (Safety Run-in)

    DOR is defined for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.

    Time frame: For an overall median time on study of 74.78 months

  4. Overall Response Rate (ORR) (Safety Run-in)

    ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: For an overall median time on study of 74.78 months

  5. Percentage of Participants With a Complete Response (CR) (Randomization Phase)

    Complete response rate (CR) based on the best overall response per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: For an overall median time on study of 61.34 months

  6. Overall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm)

    ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)

  7. MRD-negative Remission Rate in Participants Who Achieve CR Per Investigator Assessment (Randomization Phase and Treatment-Naive Arm)

    MRD-negative remission rate is defined as the percentage of participants with undetectable MRD at documented CR in participants who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)

  8. Overall Survival (OS) (Randomization Phase and Treatment-Naive Arm)

    OS is defined as the time from the date of randomization (Randomization Phase) or the first dose of study treatment (Treatment-Naïve arm) to death from any cause.

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)

  9. Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)

    DOR is defined as the time frame for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)

  10. Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)

    TTNT is defined as the duration from the date of randomization (Randomization Phase) or date of first dose of study treatment (Treatment-Naive Arm) to the start date of any anti-lymphoma treatment subsequent to study treatment. Post-treatment stem cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, or other cellular therapies were not considered subsequent anti-cancer treatments for participants responding to the study treatment (CR or PR).

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)

  11. Number of Participants With TEAEs (Randomization Phase)

    AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

    Time frame: From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 19.5 months

  12. Number of Participants With TLS TEAEs (Randomization Phase)

    Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug (SD). Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

    Time frame: From first dose of study drug until the end of treatment + 7 days, with an overall median treatment duration 19.5 months

  13. Steady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  14. Steady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  15. Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  16. Steady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  17. Steady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  18. Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  19. Steady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  20. Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  21. Steady-State PK of Venetoclax: Cmax (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  22. Steady-State PK of Venetoclax: AUC0-24 (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  23. Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  24. Steady-State PK of Venetoclax: CLss/F (Randomization Phase)

    Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

    Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose

  25. Time to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase)

    The FACT-Lym lymphoma-specific additional concerns subscale responses to all items are rated on a 5-point scale ranging from 0 "not at all" to 4 "very much". The lymphoma subscale includes 15 items and scores range from 0 to 60, with higher scores representing better functional status and well-being. A 5-point change in the Lym subscale was selected as a conservative estimate of clinically meaningful deterioration in lymphoma symptoms.

    Time frame: For an overall median time on study of 61.34 months (Randomization Phase)

  26. Duration of CR (Treatment-Naive Arm)

    Duration of CR, defined for subjects who achieve CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014) as the time from the first occurrence of CR to disease progression or death, whichever occurs first.

    Time frame: For an overall median time on study of 40.51 months

  27. Progression-free Survival (PFS) (Treatment-Naive Arm)

    PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

    Time frame: For an overall median time on study of 40.51 months

07

Results

Posted Jul 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Started15613413378
On study treatment at study closure02312126
Off treatment and on study follow up at study closure20222525
Completed22534651
Not completed134818727
Withdrew: Withdrawal by subject301197
Withdrew: Lost to follow-up11232
Withdrew: Death83677318
Withdrew: Other, not specified10120

Outcome measures

PrimaryNumber of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)

TLS events are defined as follows: * Clinical TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) with the following exceptions: * For the purpose of TLS assessment during the Safety Run-in Period, only those increases in serum creatinine \> 1.0 mg/dL from pre-treatment baseline will be considered clinical TLS. * In participants with renal dysfunction at baseline (CrCl \< 60 mL/min), clinical TLS is defined as the presence of laboratory TLS plus either seizures, cardiac dysrhythmia, or death. * Laboratory TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) for laboratory TLS, that does not resolve within 72 hours despite protocol required management.

Time frame:
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Reported as:
Count of participants · Participants
Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
ParticipantsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)10
PrimaryNumber of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)

DLT: any Grade (Gr) 3 or higher non-TLS adverse event (AE) at least possibly related to study drug occurring during the DLT assessment period with the following clarifications: Non-Hematologic DLTs: Gr ≥3 nausea, vomiting or diarrhea uncontrolled despite maximum medical supportive care and persisting \>5 days; Gr 3 fatigue persisting \>7 days; Gr 3 infection is not a DLT, however an infection with lifethreatening consequences or requiring urgent intervention (Gr 4) was considered a DLT; Treatment delay of any study drug \>7 days for toxicity. Hematologic DLTs: Gr 3 neutropenia is not a DLT, however, Gr 4 neutropenia (ANC \<500/mm\^3) lasting for \> 7 days is a DLT; Gr 3 or 4 neutropenia complicated by fever ≥38.5°C or infection; Gr 4 thrombocytopenia (\<25,000/mm\^3) that persists for \> 7 days; Gr 3 or 4 thrombocytopenia associated with Gr 2 or greater bleeding; Gr 3 anemia is not a DLT, however, Gr 4 anemia is a DLT; Treatment delay of any study drug \>7 days for hematologic toxicity.

Time frame:
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
ParticipantsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Any TEAE/Any Grade30
Any TEAE/ Grade 3+430
Any TEAE/Grade 500
Atrial fibrillation/Any Grade10
Atrial fibrillation/Grade 3+410
Atrial fibrillation/Grade 500
Infection/Any Grade10
Infection/Grade 3+410
Infection/Grade 500
Neutropenia/Any Grade10
Neutropenia/Grade 3+410
Neutropenia/Grade 500
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

Time frame:
From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
ParticipantsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Any TEAE156
Any TEAE, Grade 3155
Any Venetoclax (V) Related TEAE146
Any V Related TEAE Grade >=3134
Any Ibrutinib (I) Related TEAE135
Any I Related TEAE Grade >=3124
Any TEAE Leading to Discontinuation of Study Drug (I or V)62
Any TEAE Leading to Discontinuation of Study Drug (I only)10
Any TEAE Leading to Discontinuation of Study Drug (V only)10
Any TEAE Leading to Discontinuation of Study Drug (Both I and V)42
Any TEAE Leading to Dose Reduction of Study Drug (I or V)74
Any TEAE Leading to Dose Reduction of Study Drug (I Only)13
Any TEAE Leading to Dose Reduction of Study Drug (V Only)30
Any TEAE Leading to Dose Reduction of Study Drug (Both I and V)31
Any TEAE Leading to Dose Hold of Study Drug (I or V)144
Any TEAE Leading to Dose Hold of Study Drug (I Only)11
Any TEAE Leading to Dose Hold of Study Drug (V Only)00
Any TEAE Leading to Dose Hold of Study Drug (Both I and V)133
Any TESAE143
Any TESAE, Grade >=3142
Any TESAE, V Related91
Any TESAE, I Related101
Any TESAE, V or I Related101
Fatal TEAE10
Major Hemorrhage20
Major Hemorrhage, Grade >=320
Major Hemorrhage, TESAE20
PrimaryProgression-free Survival (PFS) (Randomization Phase)

PFS is defined as the time from the date of randomization to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

Time frame:
For an overall median time on study of 61.34 months
Reported as:
Median · months
Progression-free Survival (PFS) (Randomization Phase)
monthsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Progression-free Survival (PFS) (Randomization Phase)31.9 (22.8 to 54.5)22.1 (16.5 to 29.5)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Log Rank · p = 0.0024 (P value is from stratified log-rank test.) · Hazard ratio (hr): 0.629 · 95% CI 0.465 to 0.850
PrimaryComplete Response (CR) Rate (Treatment-Naive Arm)

CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

Time frame:
For an overall median time on study of 40.51 months
Reported as:
Number · percentage of participants
Complete Response (CR) Rate (Treatment-Naive Arm)
percentage of participantsTreatment-naive Open-label Arm
Complete Response (CR) Rate (Treatment-Naive Arm)69.2 (57.8 to 79.2)
SecondaryOverall Survival (OS) (Safety Run-in)

OS is defined as the time from the date of the first dose of study treatment to death from any cause.

Time frame:
For an overall median time on study of 74.78 months
Reported as:
Median · months
Overall Survival (OS) (Safety Run-in)
monthsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Overall Survival (OS) (Safety Run-in)52.3 (14.1 to NA)NA (1.5 to NA)
SecondaryProgression-free Survival (PFS) (Safety Run-in)

PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

Time frame:
For an overall median time on study of 74.78 months
Reported as:
Median · months
Progression-free Survival (PFS) (Safety Run-in)
monthsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Progression-free Survival (PFS) (Safety Run-in)46.9 (13.0 to NA)35.0 (1.2 to NA)
SecondaryDuration of Response (DOR) (Safety Run-in)

DOR is defined for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.

Time frame:
For an overall median time on study of 74.78 months
Reported as:
Median · months
Duration of Response (DOR) (Safety Run-in)
monthsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Duration of Response (DOR) (Safety Run-in)44.1 (12.5 to NA)NA (26.5 to NA)
SecondaryOverall Response Rate (ORR) (Safety Run-in)

ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

Time frame:
For an overall median time on study of 74.78 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) (Safety Run-in)
percentage of participantsSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at Baseline
Overall Response Rate (ORR) (Safety Run-in)80.0 (51.9 to 95.7)83.3 (35.9 to 99.6)
SecondaryPercentage of Participants With a Complete Response (CR) (Randomization Phase)

Complete response rate (CR) based on the best overall response per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

Time frame:
For an overall median time on study of 61.34 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR) (Randomization Phase)
percentage of participantsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Percentage of Participants With a Complete Response (CR) (Randomization Phase)53.7 (44.9 to 62.4)32.3 (24.5 to 41.0)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Cochran-Mantel-Haenszel · p = 0.0004 (Estimate and p-value for rate ratio are based on Cochran-Mantel-Haenszel (CMH) test adjusted for two randomization stratification factors: number of prior lines of therapy (1-2 vs \>=3) and TLS category (low risk vs increased risk) at randomization.) · Rate ratio: 1.658 · 95% CI 1.240 to 2.218For rate ratio, numerator is Ibrutinib + Venetoclax arm and denominator is Ibrutinib + Placebo arm.
SecondaryOverall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm)

ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm)
percentage of participantsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Overall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm)82.1 (74.5 to 88.2)74.4 (66.2 to 81.6)94.9 (87.4 to 98.6)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Cochran-Mantel-Haenszel · p = 0.1279 (Estimate and p-value for rate ratio are based on CMH test adjusted for two randomization stratification factors: number of prior lines of therapy (1-2 vs \>=3) and TLS category (low risk vs increased risk) at randomization.) · Rate ratio: 1.101 · 95% CI 0.973 to 1.247For rate ratio, numerator is Ibrutinib + Venetoclax arm and denominator is Ibrutinib + Placebo arm.
SecondaryMRD-negative Remission Rate in Participants Who Achieve CR Per Investigator Assessment (Randomization Phase and Treatment-Naive Arm)

MRD-negative remission rate is defined as the percentage of participants with undetectable MRD at documented CR in participants who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Reported as:
Number · percentage of participants
MRD-negative Remission Rate in Participants Who Achieve CR Per Investigator Assessment (Randomization Phase and Treatment-Naive Arm)
percentage of participantsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Bone marrow aspirate61.5 (40.6 to 79.8)28.6 (3.7 to 71.0)59.1 (36.4 to 79.3)
Peripheral blood77.4 (58.9 to 90.4)12.5 (0.3 to 52.7)76.5 (58.8 to 89.3)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Fisher Exact · p = 0.2028
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Fisher Exact · p = 0.0014
SecondaryOverall Survival (OS) (Randomization Phase and Treatment-Naive Arm)

OS is defined as the time from the date of randomization (Randomization Phase) or the first dose of study treatment (Treatment-Naïve arm) to death from any cause.

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Reported as:
Median · months
Overall Survival (OS) (Randomization Phase and Treatment-Naive Arm)
monthsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Overall Survival (OS) (Randomization Phase and Treatment-Naive Arm)44.9 (31.9 to NA)38.6 (25.2 to 52.6)NA (44.2 to NA)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Log Rank · p = 0.2669 (P value is from stratified log-rank test.) · Hazard ratio (hr): 0.832 · 95% CI 0.602 to 1.151Hazard ratio is estimated using stratified Cox regression model with treatment as the only covariate.
SecondaryDuration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)

DOR is defined as the time frame for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Reported as:
Median · months
Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)
monthsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)42.1 (28.7 to NA)27.6 (19.4 to 39.5)37.1 (30.3 to NA)
SecondaryTime to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)

TTNT is defined as the duration from the date of randomization (Randomization Phase) or date of first dose of study treatment (Treatment-Naive Arm) to the start date of any anti-lymphoma treatment subsequent to study treatment. Post-treatment stem cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, or other cellular therapies were not considered subsequent anti-cancer treatments for participants responding to the study treatment (CR or PR).

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Reported as:
Median · months
Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)
monthsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)NA (48.0 to NA)35.4 (24.7 to 49.8)NA (NA to NA)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Log Rank · p = 0.0013 (P value is from stratified log-rank test.) · Hazard ratio (hr): 0.541 · 95% CI 0.369 to 0.792Hazard ratio is estimated using stratified Cox regression model with treatment as the only covariate.
SecondaryNumber of Participants With TEAEs (Randomization Phase)

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

Time frame:
From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 19.5 months
Reported as:
Count of participants · Participants
Number of Participants With TEAEs (Randomization Phase)
ParticipantsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Any TEAE134131
Any TEAE, Grade 3113100
Any Venetoclax (V) Related TEAE112104
Any V Related TEAE Grade >=37546
Any Ibrutinib (I) Related TEAE121114
Any I Related TEAE Grade >=38358
Any TEAE Leading to Discontinuation of Study Drug (I or V)4348
Any TEAE Leading to Discontinuation of Study Drug (I only)1511
Any TEAE Leading to Discontinuation of Study Drug (V only)27
Any TEAE Leading to Discontinuation of Study Drug (Both I and V)2630
Any TEAE Leading to Dose Reduction of Study Drug (I or V)5029
Any TEAE Leading to Dose Reduction of Study Drug (I Only)1914
Any TEAE Leading to Dose Reduction of Study Drug (V Only)137
Any TEAE Leading to Dose Reduction of Study Drug (Both I and V)188
Any TEAE Leading to Dose Hold of Study Drug (I or V)10699
Any TEAE Leading to Dose Hold of Study Drug (I Only)1818
Any TEAE Leading to Dose Hold of Study Drug (V Only)64
Any TEAE Leading to Dose Hold of Study Drug (Both I and V)8277
Any TESAE8880
Any TESAE, Grade >=37673
Any TESAE, V Related3125
Any TESAE, I Related4737
Any TESAE, V or I Related4937
Fatal TEAE2218
Major Hemorrhage138
Major Hemorrhage, Grade >=3107
Major Hemorrhage, TESAE126
SecondaryNumber of Participants With TLS TEAEs (Randomization Phase)

Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug (SD). Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).

Time frame:
From first dose of study drug until the end of treatment + 7 days, with an overall median treatment duration 19.5 months
Reported as:
Count of participants · Participants
Number of Participants With TLS TEAEs (Randomization Phase)
ParticipantsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Any Grade73
Grades 3 and 463
SecondarySteady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · ng/mL
Steady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase)
ng/mLRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase)195 ± 179287 ± 230
SecondarySteady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Median · hours
Steady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase)
hoursRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase)2.00 (0.00 to 8.00)2.00 (0.750 to 6.00)
SecondarySteady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · ng·h/mL
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase)
ng·h/mLRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase)1090 ± 8701440 ± 1060
SecondarySteady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · hours
Steady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase)
hoursRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase)6.29 ± 1.926.66 ± 2.15
SecondarySteady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Median · hours
Steady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase)
hoursRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase)24.0 (7.0 to 24.0)24.0 (24.0 to 24.0)
SecondarySteady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · ng·h/mL
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase)
ng·h/mLRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase)1090 ± 8701440 ± 1060
SecondarySteady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · 1/hour
Steady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase)
1/hourRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase)0.123 ± 0.05560.114 ± 0.0332
SecondarySteady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · L/hour
Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)
L/hourRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)1020 ± 1130709 ± 651
SecondarySteady-State PK of Venetoclax: Cmax (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · ng/mL
Steady-State PK of Venetoclax: Cmax (Randomization Phase)
ng/mLRandomization Phase: Ibrutinb + Venetoclax
Steady-State PK of Venetoclax: Cmax (Randomization Phase)3620 ± 1650
SecondarySteady-State PK of Venetoclax: AUC0-24 (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · ng·h/mL
Steady-State PK of Venetoclax: AUC0-24 (Randomization Phase)
ng·h/mLRandomization Phase: Ibrutinb + Venetoclax
Steady-State PK of Venetoclax: AUC0-24 (Randomization Phase)65000 ± 32900
SecondarySteady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Median · hours
Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)
hoursRandomization Phase: Ibrutinb + Venetoclax
Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)6.00 (0.00 to 8.03)
SecondarySteady-State PK of Venetoclax: CLss/F (Randomization Phase)

Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.

Time frame:
Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Reported as:
Mean · L/hour
Steady-State PK of Venetoclax: CLss/F (Randomization Phase)
L/hourRandomization Phase: Ibrutinb + Venetoclax
Steady-State PK of Venetoclax: CLss/F (Randomization Phase)8.09 ± 4.82
SecondaryTime to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase)

The FACT-Lym lymphoma-specific additional concerns subscale responses to all items are rated on a 5-point scale ranging from 0 "not at all" to 4 "very much". The lymphoma subscale includes 15 items and scores range from 0 to 60, with higher scores representing better functional status and well-being. A 5-point change in the Lym subscale was selected as a conservative estimate of clinically meaningful deterioration in lymphoma symptoms.

Time frame:
For an overall median time on study of 61.34 months (Randomization Phase)
Reported as:
Median · months
Time to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase)
monthsRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + Placebo
Time to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase)9.3 (6.5 to 12.7)12.5 (8.3 to 17.9)
Statistical analysis
  • Randomization Phase: Ibrutinb + Venetoclax vs Randomization Phase: Ibrutinib + Placebo · Log Rank · p = 0.2861 (P value is from stratified log-rank test.) · Hazard ratio (hr): 1.169 · 95% CI 0.879 to 1.554
SecondaryDuration of CR (Treatment-Naive Arm)

Duration of CR, defined for subjects who achieve CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014) as the time from the first occurrence of CR to disease progression or death, whichever occurs first.

Time frame:
For an overall median time on study of 40.51 months
Reported as:
Median · months
Duration of CR (Treatment-Naive Arm)
monthsTreatment-naive Open-label Arm
Duration of CR (Treatment-Naive Arm)37.1 (34.0 to NA)
SecondaryProgression-free Survival (PFS) (Treatment-Naive Arm)

PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.

Time frame:
For an overall median time on study of 40.51 months
Reported as:
Median · months
Progression-free Survival (PFS) (Treatment-Naive Arm)
monthsTreatment-naive Open-label Arm
Progression-free Survival (PFS) (Treatment-Naive Arm)40.2 (29.4 to NA)

Adverse events

Collected over For an overall median duration of 69.6 months (Safety Run-in: Increased TLS Risk), 77.9 months (Safety Run-in: Low TLS Risk), 61.0 months (Randomization Phase: Ibrutinb + Venetoclax), 61.7 months (Randomization Phase: Ibrutinb + Placebo), 40.5 months (Treatment-naive Open-label Arm).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-in: Increased TLS Risk at Baseline8/15 (53.3%)15/15 (100%)15/15 (100%)
Safety Run-in: Low TLS Risk at Baseline3/6 (50%)3/6 (50%)6/6 (100%)
Randomization Phase: Ibrutinb + Venetoclax70/134 (52.2%)92/134 (68.7%)131/134 (97.8%)
Randomization Phase: Ibrutinib + Placebo78/132 (59.1%)86/132 (65.2%)127/132 (96.2%)
Treatment-naive Open-label Arm20/78 (25.6%)48/78 (61.5%)77/78 (98.7%)
Most frequent serious events
Showing 10 of 229
Most frequent serious events
EventSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
PYREXIAGeneral disorders3/150/61/1341/1323/78
PANCYTOPENIABlood and lymphatic system disorders0/151/62/1340/1320/78
RETROPERITONEAL HAEMORRHAGEGastrointestinal disorders0/151/60/1340/1320/78
CELLULITISInfections and infestations0/151/61/1342/1322/78
STAPHYLOCOCCAL BACTERAEMIAInfections and infestations0/151/61/1340/1320/78
ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications0/151/67/1342/1321/78
FALLInjury, poisoning and procedural complications2/151/61/1342/1321/78
SPLENIC RUPTUREInjury, poisoning and procedural complications0/151/60/1340/1320/78
MANTLE CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/150/615/13418/1321/78
ANAEMIABlood and lymphatic system disorders2/150/66/1342/1320/78
Most frequent other events
Showing 10 of 244
Most frequent other events
EventSafety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label Arm
DIARRHOEAGastrointestinal disorders10/155/684/13448/13237/78
NAUSEAGastrointestinal disorders5/155/643/13421/13224/78
THROMBOCYTOPENIABlood and lymphatic system disorders4/154/622/13420/1328/78
FATIGUEGeneral disorders5/154/639/13436/13230/78
HYPOMAGNESAEMIAMetabolism and nutrition disorders3/154/614/1344/13216/78
INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders3/153/612/13410/13217/78
VISION BLURREDEye disorders4/153/625/13423/1328/78
DYSPEPSIAGastrointestinal disorders1/153/619/13411/1328/78
OEDEMA PERIPHERALGeneral disorders2/153/616/13421/13214/78
ARTHRALGIAMusculoskeletal and connective tissue disorders3/153/622/13423/13212/78

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Safety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label ArmTotal
<=18 years000000
Between 18 and 65 years25414713108
>=65 years131938665258
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label ArmTotal
Female6231252589
Male9410310853277
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label ArmTotal
Hispanic or Latino1087117
Not Hispanic or Latino11511211072310
Unknown or Not Reported311416539
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Run-in: Increased TLS Risk at BaselineSafety Run-in: Low TLS Risk at BaselineRandomization Phase: Ibrutinb + VenetoclaxRandomization Phase: Ibrutinib + PlaceboTreatment-naive Open-label ArmTotal
American Indian or Alaska Native000000
Asian0023611
Native Hawaiian or Other Pacific Islander000000
Black or African American001113
White12611611568317
More than one race000000
Unknown or Not Reported301514335
08

Study locations

120 sites
  • The University of Arizona Cancer Centre-North Campus
    Tucson, Arizona 85719, United States
  • City of Hope
    Duarte, California 91010, United States
  • UCLA Department of Medicine-Hematology/Oncology
    Los Angeles, California 90095, United States
  • Orlando Health Inc.
    Orlando, Florida 32806, United States
  • The University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Barbara Ann Karmanos Cancer institute
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Stony Brook University
    New York, New York 11794, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • University of Tennessee medical Center
    Knoxville, Tennessee 37920, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98194, United States
  • The Canberra Hospital
    Canberra, Australian Capital Territory 2605, Australia
  • Border Medical Oncology Research Unit
    Albury, New South Wales 2640, Australia
  • Icon Cancer Care
    Auchenflower, Queensland 4101, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer
    Melbourne, Victoria 3000, Australia
  • St.Vincent's Hospital
    Melbourne, Victoria 3065, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • ZiekenhuisNetwerk Antwerpen (ZNA) Stuivenberg
    Antwerp, 2060, Belgium
  • AZ Sint-Jan Brugge-Oostende AV
    Bruges, 8000, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • CHU UCL Namur asbl- Mont Godinne
    Yvoir, 5530, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1 Z2, Canada
  • BC Cancer-Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Queen Elizabeth II Health Science Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • FN Brno, Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni Nemocnice (FN) Hradec Kravlove, a.s. IV. Interni hematologicka klinika
    Hradec Králové, 500 05, Czechia
  • FN Olomouc
    Olomouc, 77900, Czechia
  • FN Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Vseobecna fakultni nemocnice v Praze, l. interni klinika-klinika hematologie
    Prague, 128 08, Czechia
  • CHU CAEN-Hôpital de la Côte de Nacre
    Caen, Calvados 14033, France
  • Institut Bergonié
    Bordeaux, 33076, France
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont-Ferrand, 63003, France
  • Institut Paoli Calmettes, Service Hematologie
    Marseille, 13009, France
  • Centre Antoine Lacassagne
    Nice, 06189, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • CHU de Tours
    Tours, 37044, France
  • Kliniken Ostalb Stauferklinikum Schwab. Gmund
    Mutlangen, Baden-Wuttemberg 73557, Germany
  • Universitaetsklinikum Ulm
    Ulm, Baden-Wuttemberg 89081, Germany
  • Klinikum der Universitaet Muenchen Campus Grosshadern
    Munich, Bavaria 81377, Germany
  • Universitatsklinikum Koln
    Kerpen, Koln 50937, Germany
  • Universitaetsmedizin der Johannes Gutenberg, Langenbeckstrasse 1
    Langen, Mainz 55131, Germany
  • Gemeinschaftpraxis Haematologie und Onkologie
    Dresden, Saxony 01307, Germany
  • Vivantes Klinikum Am Urban
    Berlin, 10967, Germany
  • Charite- Universitatsmedizin Berlin, Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Universitatsklinikum Essen, Klinik fur Hamatologie
    Essen, 45147, Germany
  • Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin I
    Homburg/Saar, 66421, Germany
  • University Hospital of Alexandroupolis
    Alexandroupoli, 68100, Greece
  • 251 Air Force General Hospital
    Athens, 11525, Greece
  • General Hospital of Athens Laiko
    Athens, 11527, Greece
  • General Hospital of Athens "Alexandra"
    Athens, 11528, Greece
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • University Hospital of Patras
    Pátrai, 26504, Greece
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Semmelweis Egyetem
    Budapest, 1125, Hungary
  • Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Klinika
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat-Hematologia
    Győr, 9024, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvár, 7400, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    Szeged, 6725, Hungary
  • Markusovszky Egyetemi Oktatokorhaz, Haematologiai es Haemoszatazeologiai Osztaly
    Szombathely, 9700, Hungary
  • Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo di Alessandria
    Alessandria, Alessandria/Piemonte 15121, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    Bergamo, Bergamo/Lombardia 21427, Italy
  • Azienda Ospedaliera Universitaria di Bologna Policlinico Saint Orsola Malpighi
    Bologna, Bologna/Emilia-Romagna 40138, Italy
  • ASST degli Spedali Civili di Brescia
    Brescia, Brescia/Lombardia 25123, Italy
  • Azienda Ospedaliera S. Croce e Carle Cuneo
    Cuneo, Cuneo/Piemonte 12100, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Forli-Cesena/Emilia-Rom 47014, Italy
  • IRCCS Ospedale S. Raffaele di Milano
    Milan, Milano/Lombardia 20132, Italy
  • Asst Grande Ospedale Metropolitano Niguarda
    Milan, Milano/Lombardia 20162, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Pavia/Lombardia 27100, Italy
  • Azienda Ospedaliero Universitaria Molinette San Giovanni Battista di Torino
    Torino, Torino/Piemonte 10126, Italy
  • Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
    Udine, Udine/Friuli-Venezia Giulia 33010, Italy
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Spaarne Gasthuis
    Hoofddorp, 2134 TM, Netherlands
  • Leiden University Medical Center
    Leiden, 2333 ZA, Netherlands
  • Erasmus MC
    Rotterdam, 3015 CE, Netherlands
  • Franciscus Vlietland
    Schiedam, 3118 JH, Netherlands
  • Szpital Uniwersytecki nr 2 im. dr J. Biziela w Bydgoszcz
    Bydgoszcz, 85-168, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Oddzial Hematologiczny
    Chorzów, 41-500, Poland
  • Malopolskie Centrum Medyczne s c
    Krakow, 30-510Komisja Bioctyczn, Poland
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Kopernika w Lodzi
    Lodz, 93-513, Poland
  • Instytut Hematologii i Transfuzjologii
    Warsaw, 02-776, Poland
  • Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, PZOZ
    Wroclaw, 50-367, Poland
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
  • Hospital Universitari Germans Trias I Pujol
    Badalona, Barcelona 08916, Spain
  • ICO l'Hospitalet- Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitario de Cabuenes
    Gijón, Principality of Asturias 33203, Spain

Showing the first 100 of 120 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025 Feb;26(2):200-213. doi: 10.1016/S1470-2045(24)00682-X. PubMed 39914418 ↗
  • Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x. PubMed 34717692 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jun 2024, 84 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 84 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 13, 2017
StartActual
Jun 19, 2017
Primary completionActual
Jun 26, 2024
CompletionActual
Jun 27, 2024
Results first posted
Jul 22, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03112174
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Apr 13, 2017
Start date
Jun 19, 2017
Primary completion
Jun 26, 2024
Completion
Jun 27, 2024
Results posted
Jul 22, 2025
Last update
Jul 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion